
· Executive Brief
World Breast Cancer Research Day 2026
Move from isolated campaign activity to one connected operating plan across internal and community partners.

Leadership signal
Use World Breast Cancer Research Day to examine the system behind the message.
A public-facing observance can involve communications, operations, service lines, community partners, and leadership. Before publishing activity, align the message with real routes, available support, ownership, escalation, and the method used to answer questions that the campaign may generate.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Breast cancer research is only as strong as the system that reaches patients
World Breast Cancer Research Day celebrates the science behind better outcomes. For health system executives, it is also a reminder that research depends on operations: who is offered a trial, who can attend study visits, who is screened and whose data are counted. When those steps work only for some patients, research findings apply to fewer people than they should.
Representation remains a persistent gap. Among 732,969 subjects with reported race or ethnicity in U.S. breast cancer trials published from 2012 to 2022, 5.9% were Black, 3.1% Hispanic or Latinx and 2.3% Asian American or Pacific Islander.[9] A participation-to-prevalence ratio above 0.8 was achieved for all three minority groups in only 5.7% of trials that reported race.[9] For Black subjects alone, that threshold was reached in 44.7% of trials that reported race.[9] Results drawn from such trials may not describe how treatments work for the patients many health systems serve.
Sponsor and site data show the same pattern. Among 9,015 patients enrolled across 12 cooperative group breast cancer therapeutic trials from 2002 to 2020, 18% were aged 65 or older and 12% were Black.[5] Agreement between the patients sites served and those enrolled was low or absent for Medicare beneficiaries and older patients.[5]
This brief summarizes recent evidence on trial recruitment, community outreach, pre-screening technology, screening performance, patient advocacy and communication. It adds to the operating guidance already on this page and is written for leaders who own oncology service lines, research administration, community health and quality. The aim is to give leaders a short, practical list of operating changes that make research access and screening performance visible, measured and owned.
Current evidence
What the research says about representation and screening gaps
Reporting is improving, but inclusion lags. In 1,068 U.S. breast cancer trials with 871,683 subjects, race or ethnicity was reported in 785 trials (73.5%), rising from 68.8% in 2012 to 2016 to 79.3% in 2017 to 2022.[9] All four primary U.S. race groups were represented in 24.7% of trials, and race or ethnicity was included in outcome analysis in only 8.7%.[9] Without reporting and analysis by group, trial sponsors and health systems cannot tell whether results hold across the populations they serve.
Targeted therapy trials show sharper gaps. A systematic review of nine phase II and III trials of PARP inhibitors for BRCA-mutated breast cancer found enrollment fractions of 0.47% for White, 0.12% for Black and 0.06% for Hispanic patients.[6] Compared with White patients, the enrollment odds ratios were 0.26 for Black and 0.12 for Hispanic patients.[6] The authors raised concerns about equity and the generalizability of trial outcomes for these populations.[6]
Trial design alone does not explain these differences. In the cooperative group analysis, over half of trials were randomized and 92% had two or more drugs in the protocol, yet these features did not appear to influence enrollment of underrepresented groups.[5] Agreement between Black patients served and enrolled was moderate (weighted kappa 0.64).[5] The authors called for research to engage sites and test strategies for enrolling underrepresented patients.[5]
Screening performance shows parallel disparities. Among 663,924 screening-eligible respondents in a national survey from 2018 to 2022, sexual orientation minority status was associated with lower breast cancer screening adherence (adjusted prevalence ratio 0.84).[10] Gender identity minority status was associated with substantially lower adherence (adjusted prevalence ratio 0.24).[10] These are national survey findings, but they point to a group that many health system screening dashboards do not yet measure.
Population-level trends can move in the wrong direction. In Brazil’s public health system, mammography screening rates for women aged 40 to 49 declined between 2013 and 2020 (annual percent change -10.79).[11] Time from diagnosis to treatment exceeded 60 days in more than half of cases in all age groups.[11] Screening and research share the same lesson: access determines who benefits. The practical response for executives is to measure screening, diagnosis and trial enrollment with the same stratifiers and review them together, so that gaps at one step are not mistaken for gaps at another. Delays of that length are a reminder that research advances reach patients only when routine care pathways work.
Figure 1
Who is counted in breast cancer research
Percent of trial subjects, enrollees, participants or trials, as reported in each study. Values are copied from the cited studies [5], [8], [9]; none is estimated.
Data note. These values come from three different studies with different denominators, so this is an indirect comparison that shows the scale of underrepresentation rather than a single trend.
Limitation. Published and sponsored trial data; local site enrollment may differ.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Black subjects in U.S. breast cancer trials, 2012 to 2022 | 5.9% | 43,288 of 732,969 subjects with reported race or ethnicity in 1,068 published trials | [9] |
| Black enrollees in cooperative group therapeutic trials | 12% | 9,015 patients across 12 trials, 2002 to 2020 | [5] |
| Non-Hispanic Black participants in a national screening trial | 6% | 46,403 WISDOM participants, August 2016 to February 2023 | [8] |
| Trials with adequate inclusion of Black subjects | 44.7% | Share of trials reporting race with a participation-to-prevalence ratio above 0.8 for Black subjects | [9] |
| Trials with adequate inclusion of all three minority groups | 5.7% | Asian, Black and Hispanic subjects together | [9] |

Continuum of care
From screening to trial offer to enrollment
The research pathway begins long before a consent form. It depends on screening that finds cancers early, diagnosis that happens quickly and treatment teams that identify eligible patients. Breaks anywhere upstream reduce the pool of patients who can be offered a trial. Each of those steps has its own owner, which is why research access is rarely managed as one pathway.
Pre-screening is a common bottleneck, and technology can help. A study of case-based reasoning tools for three breast cancer trials found average areas under the curve of 84.1% for random forest models and 76.4% for target patient similarity models.[3] Positive precision remained low (13.3% and 9.9%), reflecting high false-positive rates.[3] Both approaches reached performance plateaus with only about 10 eligible patients in training data.[3] For health systems with research data warehouses, these results suggest that pre-screening tools can be built and tested with relatively small amounts of local data.
Those results suggest that automated tools can widen the net but still need human review. Research coordinators will spend time on false positives, so staffing plans should account for that work. The authors suggested combining case-based methods with query- or prompt-based screening in early recruitment phases.[3] Leaders should ask research teams to track how many flagged patients are confirmed eligible and how long each review takes.
The trial offer itself is a handoff where many patients are lost. In interviews with 21 patients who declined breast cancer trials, participants suggested improving communication, including presentation of key information, timing and provider involvement.[1] They also called for resources to address logistical burdens, such as ride-share, telehealth and compensation.[1] Those suggestions are concrete enough to test: a structured offer conversation, a standard information sheet and a logistics checklist reviewed at every offer.
Large pragmatic trials show how design can follow patient preferences. The WISDOM study enrolled 46,403 participants nationwide from August 2016 to February 2023, and 28,372 (61%) were randomized.[8] Among those who self-selected their screening arm, 89% chose risk-based screening.[8] A preference-tolerant design kept participants in the study who might otherwise have declined. Designs that respect patient choice may also improve trust among communities that have historically declined participation.
Figure 3
Why the pathway breaks
People
- Insufficient provider involvement in recruitment
- Too few navigators and community health educators
- Coordinator time absorbed by false-positive pre-screens
Process
- Trial offers without clear key information or good timing
- No comparison of site population with enrollment
- Long time from diagnosis to treatment
Technology
- Pre-screening tools with low precision
- Decision aids that patients do not review
Environment
- Transportation and time burdens of study visits
- Mistrust of health care and research systems
Policy
- No funding for participant transport or compensation
- Co-pays that deter screening
Measurement
- Race and ethnicity not reported or analyzed
- Sexual orientation and gender identity not captured in screening data
Unranked qualitative cause-and-effect diagram for the outcome in the box: Breast cancer trials and screening programs do not reach a population that reflects the patients health systems serve Causes are assembled from the cited literature [1], [3], [4], [5], [7], [9], [10]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Insufficient provider involvement in recruitment; Too few navigators and community health educators; Coordinator time absorbed by false-positive pre-screens |
| Process | Trial offers without clear key information or good timing; No comparison of site population with enrollment; Long time from diagnosis to treatment |
| Technology | Pre-screening tools with low precision; Decision aids that patients do not review |
| Environment | Transportation and time burdens of study visits; Mistrust of health care and research systems |
| Policy | No funding for participant transport or compensation; Co-pays that deter screening |
| Measurement | Race and ethnicity not reported or analyzed; Sexual orientation and gender identity not captured in screening data |
Access
Bringing trials and screening to community settings
Community-based outreach can link screening and research. In rural Oahu, a team of a community health educator, an oncology provider and a clinic research coordinator facilitated 52 outreach events with about 20,000 attendees from June 2022 to June 2023.[2] A total of 92 women were screened for a breast cancer screening trial, 12 were enrolled and an additional 32 received mammograms.[2] Participants highlighted the critical role of the community health educator in building trust.[2]
That model shows both the promise and the effort required. Large public engagement produced a modest number of trial enrollments, but it also connected women to screening they might not otherwise have received. Health systems can treat outreach as a combined screening and research investment rather than funding each separately. Measuring screening completions and trial referrals from each outreach event helps leaders judge which formats work best.
Logistical support is a recurring access theme. A systematic review of 15 studies on ethnic diversity in breast cancer trials identified financial and logistical constraints among the most frequent barriers.[7] Strategies included financial assistance and transport, decentralized trial access, and patient navigators with cultural and linguistic concordance.[7] Decentralized options, such as remote consent, local laboratory draws and telehealth study visits, can reduce the number of trips a participant must make.
Community network sites are essential to reach. The web-based decision aid trial ran in 10 community oncology research clinics that care for socioeconomically disadvantaged patients.[4] Community research networks of this kind allow trials to reach patients who do not travel to academic centers. Health systems that participate in such networks can extend research access without building new infrastructure. Leaders should confirm that community clinics have the coordinator support and pharmacy capacity that trials require.
Screening access depends on cost and convenience as well. A community advisory group of 22 adults from low-income neighborhoods in Madison, Wisconsin, generated 52 ideas to improve mammography screening.[12] High-impact, low-effort ideas included reminders, sharing positive stories, offering reassurance during mammograms and reducing co-pays.[12] These are changes most health systems can test quickly. Involving community members in choosing which changes to test also gives the organization an early read on whether a change will be noticed and trusted by the people it is meant to reach. Screening improvements also widen the pool of patients who may later be eligible for research.
Executive guidance · System route
Connect the day to an accountable system route.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Define the purpose
- Align the entry point
- Navigate across services
- Manage response
- Review the campaign
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Define the purpose
Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise.
Align the entry point
Connect every communication channel to current information and a clearly identified receiving role or team.
Navigate across services
Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Manage response
Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them.
Review the campaign
Compare intended action with local process signals and partner feedback, then document the improvement to carry forward.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Define the purpose | Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise. |
| Align the entry point | Connect every communication channel to current information and a clearly identified receiving role or team. |
| Navigate across services | Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary. |
| Manage response | Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them. |
| Review the campaign | Compare intended action with local process signals and partner feedback, then document the improvement to carry forward. |
Equity and trust
Trust, culture and language shape participation
Mistrust is one of the most consistent barriers to research participation. The systematic review of ethnic diversity in breast cancer trials identified language and health literacy limitations, mistrust of health care and research systems, and insufficient provider involvement as major barriers.[7] The authors concluded that a multilevel approach combining cultural competence, community engagement and structural change is needed.[7] Building that approach requires sustained community partnerships rather than recruitment drives tied to single studies.
Specific communities face distinct gaps. A systematic review of 41 studies with 39,324 Vietnamese participants found mammography screening rates ranging from 26% to 83%, consistently lower than the U.S. national average of 81%.[15] Late-stage diagnoses occurred in 32.9% of Vietnamese women, and culturally tailored education and patient navigator programs showed success in addressing disparities.[15] Disaggregating Asian American data by subgroup can reveal gaps that broad categories hide.
Sexual and gender minority patients also experience lower screening adherence. The national survey analysis found lower breast cancer screening adherence among both sexual orientation and gender identity minority respondents.[10] The authors called for inclusive, culturally sensitive interventions to promote equitable screening access.[10] Health systems can begin by collecting sexual orientation and gender identity data respectfully and measuring screening by those categories. Staff training on respectful data collection should come first so that patients feel safe answering.
Equity also means research reaches communities that sites already serve. The cooperative group study found that site populations did not typically match the patients enrolled on trials.[5] Comparing each site’s patient mix with its enrollment is a practical way to find the gap. Agreement for older patients and Medicare beneficiaries was weakest in that study.[5] The comparison should therefore cover age and payer as well as race. Leaders can ask each site to report its patient mix and its enrollment side by side, and to explain differences.
Trust can be built through people who share identity and culture with the community. In the Oahu program, a culturally congruent and gender concordant community health educator served as the main intermediary with rural communities.[2] Patient navigators with cultural and linguistic concordance were also among the strategies identified in the diversity review.[7] Funding those roles for the long term, not only for a single grant cycle, signals commitment to the community.

Human infrastructure
Navigators, coordinators, advocates and clinicians
Research access depends on people in roles that are often underfunded. The Oahu outreach model relied on a three-person team of a community health educator, an oncology provider and a clinic research coordinator.[2] Each role covered a different part of the pathway: trust, clinical credibility and study logistics. Community health educators and coordinators are often funded by short-term grants, which makes continuity fragile.
Patient advocates can become part of the research workforce. In a breast cancer advocacy training program, 107 participants (86%) were Black women recruited from five U.S. regions with the highest breast cancer disparities for Black women.[14] After training, breast cancer knowledge was 25% higher and screening and diagnostic knowledge 20% higher than before training.[14] Participants’ self-efficacy in medical settings increased by 24%.[14] Trained advocates can help design studies, review consent materials and lead community outreach, extending the research team’s reach.
Clinicians need training in communication and bias. Patients who declined trials suggested physician and researcher recruitment training in communication and implicit bias, along with lay patient navigators.[1] The diversity review also identified training for health care professionals to enhance cultural competence and inclusive communication.[7] Training should be practical, focused on what to say during a trial offer and how to respond to common concerns.
Provider involvement is a workforce question as much as an attitude. Insufficient provider involvement in recruitment was among the barriers in the diversity review.[7] Protected time for oncologists to discuss trials, and research coordinators who can follow up on each offer, make it easier for clinicians to participate. Tracking which clinicians offer trials and how often can identify where support is needed without assigning blame.
Technology can support but not replace this workforce. Pre-screening models identified eligible patients with high recall but low precision.[3] Coordinators still review each flagged record, so automated pre-screening shifts work rather than removing it. Workforce plans should count that review time explicitly. Coordinators who are stretched across too many studies have less time for the clear, well-timed conversations that patients who declined trials asked for, so caseload limits are part of research quality. Investment in informatics staff who can maintain and tune those tools is part of the same workforce plan.
Executive guidance · Operating dashboard
Review reliability, not campaign activity alone.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Message alignment
Do channels and partners communicate one current and appropriately bounded route?
- Candidate local measure
- Content review status, conflicting instructions, corrections, and unresolved questions.
Executive guidance · Signal
Response ownership
Does every campaign-generated request reach an accountable receiver?
- Candidate local measure
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
Executive guidance · Signal
Navigation continuity
Where does ownership become unclear as people move among information, evaluation, services, and follow-through?
- Candidate local measure
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Executive guidance · Signal
Action closure
Did leaders complete and verify the improvement selected for the campaign window?
- Candidate local measure
- Assigned action, status, evidence of completion, and post-action review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Message alignment | Executive sponsor and operational lead |
| Response ownership | Operational owner and participating teams |
| Navigation continuity | Sending and receiving owners |
| Action closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Transfer responsibility with acknowledgment and visibility.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Connect operating signals to accountable executive review.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Message alignment | Do channels and partners communicate one current and appropriately bounded route? | Executive sponsor and operational lead | At campaign launch and close |
| Response ownership | Does every campaign-generated request reach an accountable receiver? | Operational owner and participating teams | At a locally defined cadence |
| Navigation continuity | Where does ownership become unclear as people move among information, evaluation, services, and follow-through? | Sending and receiving owners | At a locally defined cadence |
| Action closure | Did leaders complete and verify the improvement selected for the campaign window? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for representative breast cancer research and screening
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Trial offer tracked for every eligible patient | Patients are never asked, and gaps by group stay hidden | Cancer center research director | Offer and enrollment rates by age, race, payer and rurality |
| Site population compared with enrollment each year | Enrollment drifts away from the community served | Research administration and quality leads | Annual site-to-enrollment comparison reviewed by committee |
| Logistical support budget for participants | Transport and time costs exclude lower-income patients | Chief financial officer with research operations | Share of participants using transport, telehealth or compensation |
| Navigator and community health educator roles funded | Outreach and trust depend on goodwill | Oncology service line leader | Navigator staffing and patients navigated per month |
| Patient advocates and community advisors engaged in design | Studies and outreach miss community priorities | Community engagement director | Advisory meetings held and recommendations adopted |
| Screening adherence stratified by sexual orientation, gender identity and language | Known gaps remain unmeasured | Chief quality officer | Stratified screening report to the board |
Control points derived from the cited evidence [1], [2], [5], [10], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating research and screening so people can act
Patient-provider communication is the most frequently cited barrier in underserved communities. A systematic review of 12 studies on breast cancer screening and treatment in U.S. underserved communities found communication challenges were the most frequently cited barrier (16 citations).[13] Cultural, religious and language issues (13) and social determinants of health (12) followed.[13] The review found that intervening with patients to enhance uptake and adherence was the most frequently reported implementation strategy, appearing in all 12 studies.[13]
Decision support tools do not automatically improve knowledge. In a stepped wedge trial in 10 community oncology clinics, 44% of decision aid arm patients reviewed the decision aid.[4] Being in the decision aid arm was not associated with higher knowledge, though it was associated with higher perceptions of feeling informed.[4] Non-White race and lower education were associated with lower knowledge.[4] The authors plan to explore the discrepancy between feeling informed and having low knowledge, especially for disadvantaged patients.[4]
That gap between feeling informed and being informed matters for research too. Trial consent depends on accurate understanding of risks, benefits and logistics. Teach-back methods, plain-language materials and time for questions can help close the gap, especially for patients with less formal education. Qualified interpreters and professionally translated materials are essential for patients whose preferred language is not English, including during consent.
Media and community channels can extend recruitment. Patients who declined trials suggested leveraging media in recruitment platforms and using mixed and online recruitment.[1] Community advisory members suggested sharing positive stories about mammography experiences as a high-impact, low-effort idea.[12] Stories from trial participants and screening patients who share the community’s background can be particularly persuasive.
Finally, communication should report back. Communities that participate in outreach, advisory groups and trials deserve to hear what changed as a result. Publishing enrollment by population, screening rates by group and the actions taken in response builds the trust that future research depends on. It also lets community members hold the organization to its commitments, which is a stronger signal than any single awareness event or campaign message. World Breast Cancer Research Day is a natural moment to share that report with patients, staff, community partners and the board.

Executive guidance · 90-day plan
Use 90 days to correct one visible operating barrier.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how World Breast Cancer Research Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how World Breast Cancer Research Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Pair recognition with a system people can trust.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Connect the message to one usable, measured, and sustained operating change.
Executive action kit · Day observance
Turn World Breast Cancer Research Day into accountable action.
Move from isolated campaign activity to one connected operating plan across internal and community partners.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Define the purpose
- Align the entry point
- Navigate across services
- Manage response
- Review the campaign
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Content review status, conflicting instructions, corrections, and unresolved questions.
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During World Breast Cancer Research Day, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
World Breast Cancer Research Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
- Observance source: worldbreastcancerresearchday.org
- 2026 healthcare observances calendar: worldbreastcancerresearchday.org
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Chen M, Reh N, Dwarampudi SR, Williams CP, Henderson N, Rocque GB, et al. Strategies for optimizing clinical trial recruitment: perspectives among patients with breast cancer. Cancer Causes & Control. 2026;37(3):52. https://doi.org/10.1007/s10552-026-02140-5
- 2.Chun K, Tran-Dang MP, Cornett P, Tashombe C, Kauhane M, AL-Adhmi A, et al. Outreach to Native Hawaiian and Pacific Islander communities to increase breast cancer screening and clinical trial awareness. BMC Cancer. 2026;26(1). https://doi.org/10.1186/s12885-026-16493-2
- 3.Guillotel LA, Lesimple T, Zekri O, Cuggia M, Campillo-Gimenez B. Case-based reasoning for clinical trial recruitment tools in oncology: When you need patients to find patients. International Journal of Medical Informatics. 2026;211. https://doi.org/10.1016/j.ijmedinf.2026.106301
- 4.Schumacher JR, Hanlon BM, Zahrieh D, Rathouz PJ, Tucholka JL, McKinney G, et al. Impact of a web-based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: an Alliance Clinical Trial (A231701CD). Cancer. 2026;132(4):e70314-e70314. https://doi.org/10.1002/cncr.70314
- 5.Caston NE, Williams CP, Azuero A, Zhao F, Lee JW, Rocque GB. Patterns of Enrollment of Traditionally Underrepresented Patients in ECOG-ACRIN Sponsored Breast Cancer Therapeutic Clinical Trials. Cancer Control. 2026;33:10732748261435696. https://doi.org/10.1177/10732748261435696
- 6.Kheirkhah Rahimabad P, Sekhon S, John E. Racial and ethnic disparities in enrollment for clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in breast cancer treatment. Cancer Causes & Control. 2026;37(9). https://doi.org/10.1007/s10552-026-02236-y
- 7.Chávez-Vélez E, Morán-Erazo C, López-Cortés A, García-Cárdenas JM, Guerrero S. Barriers and solutions to ethnic diversity in breast cancer clinical trials: a systematic review. Ethnicity & Health. 2026;31(3):245-261. https://doi.org/10.1080/13557858.2026.2630819
- 8.Fiscalini A, Blum K, Fergus K, Hiatt RA, Naeim A, Kaster A, et al. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design. NPJ Breast Cancer. 2026. https://doi.org/10.1038/s41523-026-00952-x
- 9.Dimaano K, Castillo Jr O, Moazzez A, Ozao-Choy J, Dauphine C. Examining the Representation of Minority Race and Ethnicity Groups in Breast Cancer Clinical Trials in the USA Published 2012–2022. Annals of Surgical Oncology. 2026;33(6):5541-5549. https://doi.org/10.1245/s10434-026-19214-y
- 10.Arena L, Alizai Q, Elemosho A, Chatzipanagiotou OP, Pawlik TM. Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States. Cancer. 2026;132(14):e70462. https://doi.org/10.1002/cncr.70462
- 11.Freitas-Junior R, de Melo Rocha AFB, Soares LR, da Rocha Ferreira GL. Disparities in breast cancer screening, stage at diagnosis, and treatment in Brazil: a warning of the need to change public policies. BMC Public Health. 2026;26(1). https://doi.org/10.1186/s12889-026-26805-7
- 12.Jordan L, Milton A, Elezaby M, Prout T, Owusu-Brackett N, Narayan AK. Identifying Interventions to Reduce Breast Cancer Screening Barriers using Community Centered Prioritization Exercises. Journal of Breast Imaging. 2026;8(5):550-555. https://doi.org/10.1093/jbi/wbag003
- 13.Mendonca J, Etzel M, Eldawy N, Lent A, Jimenez S, Brinzo P, et al. The role of patient–provider communication and social support in improving adherence to breast cancer screening and treatment guidelines among United States underserved communities: A systematic review. Journal of Public Health. 2026;34(6):1469-1500. https://doi.org/10.1007/s10389-025-02514-0
- 14.Edmonds MC, Karmo M, Paulicin B, Wittig L, Funez K, Warren A, et al. Engaging Patient Advocates to Reduce Breast Cancer Disparities: Opportunities to Advance Breast Cancer Research and Engagement. Journal of Cancer Education. 2026;41(1):182-189. https://doi.org/10.1007/s13187-025-02645-8
- 15.Nguyen AT, Duckworth ED, Li RA, Galiano RD. Disparities in Breast Cancer Screening, Diagnosis, and Outcomes Among Vietnamese American Women: A Systematic Review. Journal of Surgical Oncology. 2026;133(3):260-281. https://doi.org/10.1002/jso.70164
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Representation in U.S. breast cancer trials | [9] | 2026 | Current evidence | Published trials only; race reported in 73.5% of trials. |
| Cooperative group enrollment of underrepresented patients | [5] | 2026 | Current evidence | One cooperative group, 12 trials; voluntary site surveys. |
| Racial and ethnic disparities in PARP inhibitor trials | [6] | 2026 | Current evidence | Nine trials; Asian enrollment largely from Asian countries. |
| Screening adherence among sexual and gender minority adults | [10] | 2026 | Current evidence | Self-reported survey data; weighted demographic proportions do not reconcile with unweighted counts and are not cited. |
| Screening and time-to-treatment trends in Brazil | [11] | 2026 | Current evidence | Ecological public system data; not directly generalizable to U.S. systems. |
| Case-based pre-screening tools for trial eligibility | [3] | 2026 | Continuum of care | Three trials at one institution. |
| Patient-suggested recruitment strategies | [1] | 2026 | Continuum of care | Interviews with 21 patients who declined trials at one center. |
| Preference-tolerant screening trial design | [8] | 2026 | Continuum of care | Cohort characteristics and design; outcome results not reported. |
| Community outreach for screening and trial enrollment | [2] [12] | 2026 | Access | Pilot program on one island; single community advisory group. |
| Barriers and strategies for ethnic diversity in trials | [7] | 2026 | Equity and trust | Fifteen studies identified from one database. |
| Screening disparities among Vietnamese American women | [15] | 2026 | Equity and trust | Heterogeneous studies synthesized narratively. |
| Patient advocate training | [14] | 2026 | Human infrastructure | Pre-post survey without comparison group. |
| Communication barriers and decision aids | [13] [4] | 2026 | Public communication | Review of 12 studies; decision aid reviewed by 44% of eligible patients. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

